In conclusion, we have designed and optimized an NCR1-based chimeric receptor that enables the targeting of malignancies of diverse histology and we are confident that the development of such non-MHC restricted tumor-targeting strategies will be beneficial to adoptive transfer treatments based on engineered T- lymphocytes. The gene discussed is HLA-C; the disease is neoplasm.